INT120562

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2002
Last Reported 2010
Negated 0
Speculated 5
Reported most in Body
Documents 108
Total Number 114
Disease Relevance 79.38
Pain Relevance 3.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (Egfr) cell morphogenesis (Egfr) Golgi apparatus (Egfr)
endoplasmic reticulum (Egfr) intracellular (Egfr) enzyme binding (Egfr)
Anatomy Link Frequency
skin 7
head 3
A549 3
lung 3
neck 3
Egfr (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 50 100.00 Very High Very High Very High
cINOD 38 99.88 Very High Very High Very High
imagery 291 99.20 Very High Very High Very High
qutenza 12 98.96 Very High Very High Very High
Inflammation 66 98.72 Very High Very High Very High
metalloproteinase 60 98.50 Very High Very High Very High
fibrosis 118 97.04 Very High Very High Very High
positron emission tomography 95 91.48 High High
substance P 4 87.92 High High
Opioid 52 87.60 High High
Disease Link Frequency Relevance Heat
Cancer 5493 99.92 Very High Very High Very High
Malignant Neoplastic Disease 405 99.92 Very High Very High Very High
Pancreatic Cancer 3081 99.84 Very High Very High Very High
Exanthema 1490 99.84 Very High Very High Very High
Non-small-cell Lung Cancer 1206 99.84 Very High Very High Very High
Solid Tumor 355 99.84 Very High Very High Very High
Colon Cancer 308 99.84 Very High Very High Very High
Carcinoma 118 99.84 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 450 99.70 Very High Very High Very High
Breast Cancer 218 99.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Erlotinib is a low molecular weight quinazolin derivative which acts to selectively and reversibly inhibit of EGFR tyrosine kinase activity (Grunwald and Hidalgo 2003; Pao and Miller 2005).
Negative_regulation (inhibit) of EGFR
1) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.74 Pain Relevance 0
A therapeutic role has now been established for EGFR inhibitors in carcinomas of the head and neck, lung, breast, and colon.
Negative_regulation (inhibitors) of EGFR in head associated with carcinoma
2) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.72 Pain Relevance 0
Mechanisms of pharmacologic EGFR inhibition
Negative_regulation (inhibition) of EGFR
3) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.57 Pain Relevance 0
The mechanism of association between rash and improved outcome in EGFR inhibition remains unclear.
Negative_regulation (inhibition) of EGFR associated with exanthema
4) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 1.31 Pain Relevance 0
Preclinical data of EGFR inhibition by TKIs in pancreatic cancer
Negative_regulation (inhibition) of EGFR associated with pancreatic cancer
5) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.98 Pain Relevance 0
With the approval of erlotinib for treatment of pancreatic cancer in 2005, EGFR inhibition has now become an appropriate strategy for pancreatic cancer as well.


Negative_regulation (inhibition) of EGFR associated with pancreatic cancer
6) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.71 Pain Relevance 0
Agents that have been rigorously evaluated in phase III study designs include matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, angiogenesis inhibitors, and inhibitors of the epidermal growth factor receptor (EGFR), with myriad other targeted therapies under active investigation in earlier phases of testing.
Negative_regulation (inhibitors) of EGFR associated with metalloproteinase
7) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.32 Pain Relevance 0.05
The challenge remains how to identify the subset of advanced pancreatic cancer patients most likely to benefit from EGFR inhibition.
Negative_regulation (inhibition) of EGFR associated with pancreatic cancer
8) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 1.09 Pain Relevance 0
Another potential molecular predictor of response to therapeutic EGFR inhibition is the presence or absence of mutant K-ras.
Negative_regulation (inhibition) of EGFR
9) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.33 Pain Relevance 0
This article will review the molecular mechanism of EGFR inhibition as a therapeutic approach in solid tumors; the preclinical data supporting EGFR inhibition in solid tumors including pancreatic cancer; and finally, the clinical trials that have established the small molecule TKI erlotinib as an approved therapy for advanced pancreatic cancer.


Negative_regulation (inhibition) of EGFR associated with pancreatic cancer and solid tumor
10) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.78 Pain Relevance 0
Agents that have been rigorously evaluated in phase III study designs include matrix metalloproteinase inhibitors, farnesyl transferase inhibitors, angiogenesis inhibitors, and inhibitors of the epidermal growth factor receptor (EGFR), with myriad other targeted therapies under active investigation in earlier phases of testing.
Negative_regulation (inhibitors) of epidermal growth factor receptor associated with metalloproteinase
11) Confidence 0.59 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727779 Disease Relevance 0.32 Pain Relevance 0.05
There were no differences in the intensity of fluorescence in the control groups, i.e.: both of the transfection reagent control as well as unrelated dsRNA group, did not show any significant decrease (P > 0.05) (Fig. 1B &1C), suggesting the reduction of the EGFR protein was significant and specific.
Negative_regulation (reduction) of EGFR
12) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.13 Pain Relevance 0
Further molecular analyses revealed that the down-regulation of EGFR expression was the result of a marked decrease in the transcriptional activity of EGFR.
Negative_regulation (decrease) of EGFR
13) Confidence 0.59 Published 2005 Journal Genet Vaccines Ther Section Body Doc Link PMC1187910 Disease Relevance 0.13 Pain Relevance 0
Dietary administration of this NSAID also inhibited Egfr activity in tumors.
Negative_regulation (inhibited) of Egfr associated with cancer and cinod
14) Confidence 0.57 Published 2004 Journal J. Biol. Chem. Section Abstract Doc Link 15294912 Disease Relevance 1.17 Pain Relevance 0.10
Because EGFR inhibition can downregulate HIF-1?
Negative_regulation (inhibition) of EGFR
15) Confidence 0.57 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2716529 Disease Relevance 1.01 Pain Relevance 0
Conversely, pharmacological inhibition of EGFR can decrease VEGF expression and consequently angiogenesis in many tumor types [16]–[20].
Negative_regulation (inhibition) of EGFR associated with cancer
16) Confidence 0.57 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2716529 Disease Relevance 1.03 Pain Relevance 0
As discussed above, EGFR inhibition has been shown to have numerous effects that could lead to increased in vitro radiosensitization.
Negative_regulation (inhibition) of EGFR
17) Confidence 0.57 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2716529 Disease Relevance 0.57 Pain Relevance 0
Specific inhibition of EGFR and TRPV1 indicated that capsaicin-induced ERK activation in A431 cells was dependent on EGFR, but not TRPV1.
Negative_regulation (inhibition) of EGFR in A431 associated with qutenza
18) Confidence 0.57 Published 2010 Journal Cancer Res. Section Abstract Doc Link 20660715 Disease Relevance 0.78 Pain Relevance 0.78
Lapatinib may have a therapeutic advantage over erlotinib because it acts as a dual inhibitor of EGFR (or HER-1) and HER-2 (ErbB2) tyrosine kinases.
Negative_regulation (inhibitor) of EGFR
19) Confidence 0.55 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 1.12 Pain Relevance 0
Previous studies have shown that EGFR or HER-2 inhibition may potentiate the effect of radiation therapy [10].
Negative_regulation (inhibition) of EGFR
20) Confidence 0.55 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2883966 Disease Relevance 0.69 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox